SOAT1 and hematologic disorder: JAK inhibitors selectively inhibit JAK kinase, block the JAK/STAT signaling pathway, and are used clinically to screen drugs for the treatment of hematological disorders, oncology, rheumatoid arthritis, and psoriasis.